Search results for: Health Policy and Regulation
Filter search results
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
…launch of new and more effective presentations and indications. Consequently, we suggest that pricing and reimbursement decisions should consider how to recognise the dynamic nature of pharmaceutical markets and the…
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
…evaluate the clinical and economic value of health care interventions − prescription drugs, diagnostic tests, and a range of others − and innovations in the delivery of care. ICER involves…
OHE This Week: BioWales 2013, UK Medicines Market and EQ-5D in Asia
18 March 2013
…March: Nancy Devlin will be in Singapore with EuroQol colleagues. The symposium with Asian researchers and policy makers will discuss the EQ-5D and explore its potential in Asia. Until 12…
Disability Adjusted Life Years (DALYs) for Decision-Making?
9 January 2002
Disability-adjusted life years (DALYs) were introduced in 1993 amid the pages and policy directives of the World Development Report ‘Investing in Health’ (World Bank, 1993). DALYs are a measure of…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
The UK and Germany are the European leaders in biotechnology. They have many more companies and employees in biotechnology, and much greater sums invested in biotechnology research and development (R&D)…
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
…Trusts (PCTs) in England?” If we can estimate the health gain achieved from additional health spending we can better understand the potential health consequences of spending money on other things…
OHE is Recruiting for Two Positions: A Deputy Director and an Economist.
26 March 2015
…and energetic economist, for the role of deputy to the Director of the OHE. Managerial experience within a research and consultancy setting in the health and/or life sciences sector is…
OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs
12 May 2015
…sharing and performance based arrangements (PBRSAs), including trends, and the challenges involved in putting them in place. Several examples of performance-based schemes from Europe, the United States, and Australia will…
OHE at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad
19 June 2015
…Annual Meeting, Global Efforts in Knowledge Transfer: HTA to Health Policy and Practice, took place on 15-17 June 2015 in Oslo. Members of the OHE team attended and presented key…